CommercialPrior AuthMedium impact
Pegvaliase-pqpz (Palynziq) (CPB 0933, reviewed 2026-06-09)
Aetna·Endocrinology, Genetics, Pediatrics +1 more·Medical Policy
Effective date
Jun 9, 2026
We identified it
Aug 13, 2026
Summary
Aetna has issued a new clinical policy (CPB 0933, effective 2026-06-09) establishing coverage criteria for Pegvaliase-pqpz (Palynziq) in treating phenylketonuria (PKU). The policy requires patients to be 12+ years old with confirmed PKU diagnosis and baseline blood phenylalanine >600 micromol/L, must be prescribed by metabolic disease/PKU specialists, and requires documented clinical response or continued titration for coverage continuation. Prior to this policy, coverage criteria for this medication may have been unclear or absent.
Action Required
By 2026-06-09: Billing team must implement prior authorization requirements for Palynziq claims in the billing system. (1) Configure system to require prior auth documentation including: patient age (≥12 years), confirmed PKU diagnosis with blood phenylalanine >600 micromol/L baseline, and prescriber specialty verification (metabolic disease or PKU specialist). (2) Update claim submission templates to capture baseline phenylalanine levels and confirm Kuvan discontinuation (if applicable). (3) For continuation of therapy claims, require documentation of either: clinical response (phenylalanine ≤600 micromol/L) OR evidence of ongoing titration with documentation that patient has not exceeded 16 weeks at maximum 60mg dose. (4) Ensure billing software flags any claims billing Palynziq concurrently with Kuvan for denial. (5) Train billing staff on age requirement (12+) and metabolic specialist requirement for authorization. (6) Establish process to track 16-week maximum titration period at 60mg dose for automatic discontinuation flagging. Failure to obtain prior authorization or submit required documentation will result in claim denials. Providers must submit prescriber credentials confirming metabolic disease or PKU specialty.